Jaguar health reports 2021 third quarter financial results

Mytesi ® prescription volume increased 7.6% in q3 2021 over q2 2021 third quarter 2021 mytesi net and gross sales were approximately $0.6 million and approximately $3.2 million company expects to complete transition to selling mytesi through closed specialty pharmacy network by end of 2021 as part of company's market access strategy upcoming december 2021 milestones: presentation of phase 2 halt-d study results at san antonio breast cancer symposium & launch of canalevia™-ca1 for chemotherapy-induced diarrhea in dogs reminder: jaguar to host investor webcast today (wednesday, november 17th) at 8:30 a.m. eastern regarding third quarter 2021 financials & business updates; click here to register for webcast san francisco, ca / accesswire / november 17, 2021 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today reported consolidated third quarter 2021 financial results.
JAGX Ratings Summary
JAGX Quant Ranking